Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: J Cancer Surviv. 2018 Sep 4;12(6):744–752. doi: 10.1007/s11764-018-0711-y

Table 2.

Participant characteristics by the 12-item Physical Activity Barriers After Cancer (PABAC) scale scores

Characteristic No. (% of total) PABAC score Mean (SD) p value
Age, years 0.04
 Mean ± standard deviation 60.4 ± 11.6
 <60 297 (44.9) 27.3 (4.8)
 ≥60 365 (55.1) 26.3 (5.2)
Sex 0.02
 Male 231 (34.9) 26.0 (5.3)
 Female 431 (65.1) 27.2 (4.8)
Race 0.04
 White 539 (81.4) 26.6 (5.1)
 Non-White 123 (18.6) 27.9 (4.9)
Body Mass Index (kg/m2) 0.08
 Normal weight (< 25) 230 (35.0) 26.2 (5.2)
 Overweight/Obese (≥ 25) 428 (65.0) 27.1 (5.0)
Education 0.03
 High school or less 212 (32.4) 27.7 (4.3)
 Some college or above 442 (67.6) 26.5 (5.3)
Relationship Status 0.07
 Partnered 431 (65.2) 26.5 (5.1)
 Not partnered 230 (34.8) 27.4 (4.9)
Cancer Type 0.25
 Breast 206 (31.2) 27.0 (5.3)
 Thoracic/Lung 98 (14.8) 26.9 (4.6)
 Hematologic 97 (14.7) 25.6 (5.0)
 Other* 260 (39.3) 27.1 (5.0)
Cancer Stage 0.18
 Non-metastatic 323 (53.2) 27.1 (5.0)
 Metastatic 284 (46.8) 26.5 (5.0)
Time since Cancer Diagnosis 0.02
 ≤ 12 months 318 (49.6) 27.4 (4.7)
 > 12 months 323 (50.4) 26.2 (5.3)
Cancer Treatment Status 0.30
 Currently receiving treatment 501 (80.0) 27.1 (4.8)
 Completed treatment 111 (17.7) 25.9 (5.7)
 About to start treatment 14 (2.3) 27.1 (5.5)
Chemotherapy 0.24
 Yes 579 (87.5) 26.9 (5.1)
 No 83 (12.5) 26.0 (4.8)
Radiation 0.31
 Yes 352 (53.2) 26.6 (4.6)
 No 310 (46.8) 27.1 (5.5)
Surgery 0.001
 Yes 348 (52.6) 27.6 (5.2)
 No 314 (47.4) 25.9 (4.7)
Hospital Treatment Location 0.03
 Academic 321 (48.5) 26.2 (5.2)
 Community 341 (51.5) 27.3 (4.9)
Met physical activity recommendations in the past month <0.001
 Yes 160 (25.3) 25.32 (5.9)
 No 473 (74.7) 27.34 (4.6)

Due to missing data, some variables do not add up to 662.

*

Other cancer type includes but is not limited to: gastrointestinal, gynecological, genitourinary, head and neck, sarcoma, and skin.